Go Pro
→ Gold majors have a big problem (From Golden Portfolio) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.11 0.00 (-2.61%)
As of 09/11/2026 12:44 PM Eastern
Compare

OBD vs. IXI, FAB, NSCI, CLBX, and APTA

Should you buy Oxford BioDynamics stock or one of its competitors? Oxford BioDynamics's main competitors and comparable companies include IXICO (IXI), Fusion Antibodies (FAB), NetScientific (NSCI), Cellbxhealth (CLBX), and Aptamer Group (APTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to IXICO?

Oxford BioDynamics (LON:OBD) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

11.7% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 30.6% of IXICO shares are held by institutional investors. 52.8% of Oxford BioDynamics shares are held by insiders. Comparatively, 3.1% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IXICO had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
IXICO Neutral

IXICO has a net margin of -24.98% compared to Oxford BioDynamics' net margin of -825.61%. IXICO's return on equity of -16.18% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
IXICO -24.98%-16.18%-10.40%

IXICO has higher revenue and earnings than Oxford BioDynamics. IXICO is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M4.02-£103.52M-£0.20N/A
IXICO£7.28M2.16-£3.58M-£1.95N/A

Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, IXICO has a beta of 0.106, meaning that its stock price is 89% less volatile than the broader market.

Summary

IXICO beats Oxford BioDynamics on 7 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Fusion Antibodies has a net margin of -91.92% compared to Oxford BioDynamics' net margin of -825.61%. Fusion Antibodies' return on equity of -210.32% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Oxford BioDynamics -825.61%-451.74%-56.23%

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 52.8% of Oxford BioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Fusion Antibodies has a beta of 1.244, indicating that its share price is 24% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

In the previous week, Fusion Antibodies had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Oxford BioDynamics. Fusion Antibodies' average media sentiment score of 1.68 beat Oxford BioDynamics' score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the media.

Company Overall Sentiment
Fusion Antibodies Very Positive
Oxford BioDynamics Neutral

Fusion Antibodies has higher revenue and earnings than Oxford BioDynamics. Fusion Antibodies is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.90-£4.10M-£1.50N/A
Oxford BioDynamics£1.20M4.02-£103.52M-£0.20N/A

Summary

Fusion Antibodies beats Oxford BioDynamics on 8 of the 13 factors compared between the two stocks.

How does Oxford BioDynamics compare to NetScientific?

NetScientific (LON:NSCI) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Oxford BioDynamics Neutral

NetScientific has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

NetScientific has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
Oxford BioDynamics£1.20M4.02-£103.52M-£0.20N/A

14.7% of NetScientific shares are held by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are held by institutional investors. 42.4% of NetScientific shares are held by company insiders. Comparatively, 52.8% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NetScientific has a net margin of -182.91% compared to Oxford BioDynamics' net margin of -825.61%. NetScientific's return on equity of -13.70% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Oxford BioDynamics -825.61%-451.74%-56.23%

Summary

NetScientific beats Oxford BioDynamics on 8 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to Cellbxhealth?

Cellbxhealth (LON:CLBX) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Oxford BioDynamics Neutral

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Comparatively, 52.8% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cellbxhealth has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Cellbxhealth's return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Oxford BioDynamics -825.61%-451.74%-56.23%

Cellbxhealth has higher earnings, but lower revenue than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M11.18N/A-£3.49N/A
Oxford BioDynamics£1.20M4.02-£103.52M-£0.20N/A

Summary

Cellbxhealth beats Oxford BioDynamics on 5 of the 9 factors compared between the two stocks.

How does Oxford BioDynamics compare to Aptamer Group?

Oxford BioDynamics (LON:OBD) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.871, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Aptamer Group Neutral

Aptamer Group has a net margin of -178.52% compared to Oxford BioDynamics' net margin of -825.61%. Aptamer Group's return on equity of -135.35% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Aptamer Group -178.52%-135.35%-44.96%

11.7% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 3.4% of Aptamer Group shares are held by institutional investors. 52.8% of Oxford BioDynamics shares are held by insiders. Comparatively, 7.6% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aptamer Group has higher revenue and earnings than Oxford BioDynamics. Aptamer Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M4.02-£103.52M-£0.20N/A
Aptamer Group£1.38M8.93-£14.17M-£0.11N/A

Summary

Aptamer Group beats Oxford BioDynamics on 8 of the 11 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£4.81M£3.86B£7.15B£2.87B
Dividend YieldN/A3.63%2.56%6.23%
P/E Ratio-0.5614.11272.98366.83
Price / Sales4.021,464.08649.9783,599.70
Price / Cash3.98106.6877.0427.89
Price / Book0.1415.1310.336.33
Net Income-£103.52M-£22.82M£3.49B£5.89B
7 Day Performance-3.45%-4.31%-3.33%-0.69%
1 Month Performance-20.00%0.00%-0.42%0.18%
1 Year Performance-75.11%40.67%19.22%20.03%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.11
-2.6%		N/A-75.1%£4.81M£1.20MN/A45
IXI
IXICO
N/AGBX 8
+6.7%		N/A-40.2%£17.52M£7.28MN/A89
FAB
Fusion Antibodies
N/AGBX 11.50
-2.1%		N/A-28.3%£14.39M£1.60MN/A48
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
CLBX
Cellbxhealth
N/AGBX 1.13
-2.2%		N/AN/A£12.79M£1.15MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Elon’s “nude” scandal – a big opportunity?
Elon Musk's SpaceX just hit a legal snag in Minnesota over Grok's AI nudification capabilities, with the state...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...
Behind the Markets | Sponsoredtc pixel
I called NVDA at $6 - Here's what’s next…
Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel